GlaxoSmithKline and Adolor Corp. achieved top-line results from two Phase III registration studies (012 and 013) of alvimopan (Entereg/Entrareg) for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic non-cancer pain. Study 012 achieved statistical significance for the primary endpoint — the proportion of patients who had a weekly average of three or more spontaneous bowel movements (SBM) defined as bowel movements with no laxative in the previous 24 hours and ...